vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Frequently asked questions
What sector does vTv Therapeutics Inc (VTVT) operate in?
vTv Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is vTv Therapeutics Inc (VTVT) current stock price?
As of the latest data, vTv Therapeutics Inc stock price is $25.81, with a previous close of $25.55. vTv Therapeutics Inc gained $0.26 in the last trading session, representing a 1.02% increase.
What is vTv Therapeutics Inc (VTVT) current market capitalization?
vTv Therapeutics Inc market cap is approximately 102.05 million.
What is vTv Therapeutics Inc (VTVT) Earnings Per Share (EPS)?
The trailing EPS is -$0.76, and the forward EPS is -$4.29.
What is vTv Therapeutics Inc (VTVT) EBITDA?
vTv Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -13.05 million.
Does vTv Therapeutics Inc (VTVT) pay dividends?
No. vTv Therapeutics Inc does not pay a dividend.
What is vTv Therapeutics Inc (VTVT) beta (volatility) score?
vTv Therapeutics Inc has a beta of 0.285, indicating lower volatility than the overall market.
